196 related articles for article (PubMed ID: 25833404)
41. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
Guerrero MI; Colorado CL; Torres JF; León CI
Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
[TBL] [Abstract][Full Text] [Related]
42. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
43. Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy.
Balakrishnan S; Seshadri PS; Neelan PN; Venkataramaniah HN; Harikrishnan S; Bhatia VN
Lepr India; 1983 Jan; 55(1):71-5. PubMed ID: 6348413
[TBL] [Abstract][Full Text] [Related]
44. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985.
Guelpa-Lauras CC; Cartel JL; Constant-Desportes M; Millan J; Bobin P; Guidi C; Brucker G; Flageul B; Guillaume JC; Pichet C
Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):672-9. PubMed ID: 3323369
[TBL] [Abstract][Full Text] [Related]
45. Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep.
Jouet A; Braet SM; Gaudin C; Bisch G; Vasconcellos S; Epaminondas Nicacio de Oliveira do Livramento RE; Prado Palacios YY; Fontes AB; Lucena N; Rosa P; Moraes M; La K; Badalato N; Lenoir E; Ferré A; Clément M; Hasker E; Grillone SH; Abdou W; Said A; Assoumani Y; Attoumani N; Laurent Y; Cambau E; de Jong BC; Suffys PN; Supply P
EBioMedicine; 2023 Jul; 93():104649. PubMed ID: 37327675
[TBL] [Abstract][Full Text] [Related]
46. [Advances in the chemotherapy of leprosy].
Grosset J
Med Trop (Mars); 1984; 44(1):17-22. PubMed ID: 6377002
[TBL] [Abstract][Full Text] [Related]
47. Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis.
Li X; Li G; Yang J; Jin G; Shao Y; Li Y; Wei P; Zhang L
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293307
[TBL] [Abstract][Full Text] [Related]
48. Report of rpoB mutation in clinically suspected cases of drug resistant leprosy: a study from Eastern India.
Hasanoor Reja AH; Biswas N; Biswas S; Lavania M; Chaitanya VS; Banerjee S; Maha Patra PS; Gupta UD; Patra PK; Sengupta U; Bhattacharya B
Indian J Dermatol Venereol Leprol; 2015; 81(2):155-61. PubMed ID: 25751332
[TBL] [Abstract][Full Text] [Related]
49. Treatment of leprosy.
Kar HK; Gupta R
Clin Dermatol; 2015; 33(1):55-65. PubMed ID: 25432811
[TBL] [Abstract][Full Text] [Related]
50. [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique].
Constant-Desportes-Relouzat M; Grosset J; Guelpalauras CC; Salvini B; Cales-Quist D
Acta Leprol; 1986; 4(3):293-300. PubMed ID: 3551468
[No Abstract] [Full Text] [Related]
51. Drug resistance in patients with leprosy in the United States.
Williams DL; Lewis C; Sandoval FG; Robbins N; Keas S; Gillis TP; Scollard DM
Clin Infect Dis; 2014 Jan; 58(1):72-3. PubMed ID: 24065328
[TBL] [Abstract][Full Text] [Related]
52. Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015.
Chauffour A; Lecorche E; Reibel F; Mougari F; Raskine L; Aubry A; Jarlier V; Cambau E;
Clin Microbiol Infect; 2018 Nov; 24(11):1213.e5-1213.e8. PubMed ID: 29906598
[TBL] [Abstract][Full Text] [Related]
53. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
[TBL] [Abstract][Full Text] [Related]
54. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
55. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
[No Abstract] [Full Text] [Related]
56. Activity of the combination of isoniazid, protionamide and dapsone against Mycobacterium leprae and some other mycobacteria.
Pattyn SR; Portaels F; Van Loo G; Van den Breen L
Arzneimittelforschung; 1981; 31(12):2155-7. PubMed ID: 7037011
[TBL] [Abstract][Full Text] [Related]
57. Infectivity of secondary dapsone-resistant cases.
Jesudasan K; Pannikar V; Christian M
Int J Lepr Other Mycobact Dis; 1988 Sep; 56(3):418-21. PubMed ID: 3047282
[TBL] [Abstract][Full Text] [Related]
58. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
59. Primary dapsone resistance in leprosy.
Vaishnavi C; Ganguly NK; Kumar B; Kaur S; Chakravarti RN
Indian J Lepr; 1985; 57(3):507-13. PubMed ID: 3913705
[TBL] [Abstract][Full Text] [Related]
60. [Sulfone-resistance of Mycobacterium leprae--monotherapy with diaminodiphenylsulfone--the value of triple-drug combinations].
Floch HA
Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):122-5. PubMed ID: 3519797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
